title: The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.
abstract: Antiretroviral therapy programs in Africa are currently providing treatment for almost two million people. The long-term success of large scale antiretroviral therapy programs in sub-Saharan Africa remains uncertain because of the limited information currently available on rates of virologic failure and selection for drug-resistant variants in the different HIV subtypes. This article provides a comprehensive review of the published literature on the prevalence of primary and secondary HIV drug resistance with different subtypes and in various settings across sub-Saharan Africa.
authors.affiliation: Infectious Diseases Institute, Kampala, Uganda. hsendagire@idi.co.ug
authors.forename: Hakim
authors.initials: H
authors.lastname: Sendagire
authors.forename: Philippa J
authors.initials: PJ
authors.lastname: Easterbrook
authors.forename: Immaculate
authors.initials: I
authors.lastname: Nankya
authors.forename: Eric
authors.initials: E
authors.lastname: Arts
authors.forename: David
authors.initials: D
authors.lastname: Thomas
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Reynolds
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D010641:Phenotype; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors